Histological subtype is the most important determinant of survival in metastatic papillary thyroid cancer by Chrisoulidou, Alexandra et al.
RESEARCH Open Access
Histological subtype is the most important
determinant of survival in metastatic papillary
thyroid cancer
Alexandra Chrisoulidou
1†, Maria Boudina
1†, Athanasios Tzemailas
2, Eleni Doumala
1, Pashalia K Iliadou
1,
Frideriki Patakiouta
3 and Kalliopi Pazaitou-Panayiotou
1*
Abstract
Background: Papillary thyroid cancer (PTC) comprises the commonest type of thyroid cancer and carries the
highest rate of survival. However, when metastatic disease occurs, survival is significantly affected.
Methods: We aimed to identify prognostic histopathological and clinical factors that modify survival in metastatic
PTC. All cases of metastatic PTC treated at our department in the last 20 years were reviewed and analyzed.
Results: Histological subtype was the most important determinant of survival, as classic PTC demonstrated clearly
improved survival compared to follicular subtype of PTC and other less frequently seen histological subtypes. The
instant risk of death for the other histological subtypes was 4.56 times higher than the risk for the classic papillary
type. Overall, a 10-year survival of 76.6% in our patients was seen.
Conclusions: Patients with aggressive variants of PTC are more at risk for the development of metastatic disease.
In these patients, established treatment modalities (surgery, radioiodine therapy) should be offered promptly, as
well as close follow-up.
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Background
Differentiated thyroid cancer, comprising papillary and
follicular thyroid cancer, generally carries a good prog-
nosis. Papillary thyroid cancer (PTC) is the most fre-
quent type of thyroid malignancy and its metastases are
usually lymphatic [1]. The risk of distant metastases,
usually to the lung, mediastinal lymph nodes and bone,
is greater in follicular than in papillary carcinoma [2].
Distant metastases from PTC may occur with a fre-
quency ranging from 1.73-8.4% in most studies [3,4].
The most common site of distant metastases from PTC
is the lung followed by mediastinal lymph nodes [5].
Less often, distant metastases may appear in bones [6],
central nervous system [7,8], liver [9], pericardium and
pleura [10], kidney [11], pancreas [12], skin and muscle
[13], gastrointestinal tract [14]. As effective treatment
may not exist for many of these patients, it is of para-
mount importance to identify, if possible, those who are
at greater risk for developing metastatic disease.
A limited number of retrospective studies have ana-
lyzed the prognostic factors, which affect clinical out-
come in metastatic PTC. Progn o s t i cf a c t o r sa ss e xa n d
age, tumor size, histologic type, tumor infiltration, vas-
cular or lymphatic invasion, have been shown to affect
survival in these patients [15]. However, most studies
looked into prognostic factors in differentiated thyroid
cancer, including both papillary and follicular thyroid
cancer in the analysis. In recent years, marked differ-
ences in prognostic factors, clinicopathologic features
and treatment necessitate the distinction of these two
entities [4]. Even in patients with metastatic disease, the
overall survival in papillary thyroid cancer is higher than
in follicular cancer [16].
In this retrospective study we aimed to investigate
patients with metastatic PTC only in order to delineate
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entity. Within this group, we subdivided patients
according to histologic subtype, and studied the clinical
and histological characteristics and the received treat-
ment modalities during a mean follow-up of 9 years.
Using multivariate analysis, we estimated the factors
that significantly affect survival in metastatic PTC.
Patients and methods
We retrospectively reviewed the records of 1550 patients
who had PTC. From this cohort, we identified 52
patients (29 females and 23 males) who presented with
or developed (during follow up) distant metastatic dis-
ease. For all patients we collected data regarding histolo-
gical features, age at diagnosis, site of distant metastases,
treatment modalities and outcome of the disease. All
patients were followed up at the Department of
Endocrinology & Endocrine Oncology of Theagenio
Cancer Hospital from 1988-2009. Patients’ characteris-
tics are shown in Table 1. Tumor, lymph nodes and
metastases (TNM) staging at the time of diagnosis is
shown in table 2.
The diagnosis of distant metastases was based on
whole body scan findings and elevated thyroglobulin
levels and was verified by computed tomography or
MRI. Whenever feasible, biopsy of the metastatic lesions
confirmed the diagnosis. Upper mediastinal metastases
were not considered as distant. Metastases were classi-
fied according to the site of involvement. Histological
classification was in accordance with WHO classification
2004 [17].
In all patients work-up included 1) measurements of
thyroglobulin, TSH and free thyroxine on suppressive
therapy and 2) neck ultrasound annually. Diagnostic
Table 1 Characteristics of the 52 patients with metastatic PTC
Number of patients Number of deaths (%)
Age (years)
> 19 7 (4F/3M) 1 (1M) (14.3%)
19-45 10 (6F/4M) 4 (3F/1M) (40.0%)
< 45 35 (19F/16M) 16 (6F/10M) (45.7%)
Sex
Males 23 12
Females 29 9
Histology
Classic papillary 24
Follicular variant 20
Papillary with low differentiation of the cells 6
Insular 1
Columnar 1
Size of tumor (mm) 33 (7-80)
Multifocal tumors 27 (15F/12M)
Bilateral tumors 25 (13F/12M)
Invasion of tumor capsule 4
Absence of tumor capsule 34
Thyroid capsule invasion 43
Extrathyroidal invasion 38
Vascular infiltration 17
Presence of metastases
At diagnosis 17
During follow-up 35
Years of follow-up (years) 8 (1-29)
Thyroidectomy
TT 46
NTT 6
Total RAI dose (mCi) 360 (100-1500)
Thyroglobulin at 1
st RAI 121 (1.9-4000)
Data as median (range); F: female, M: male, TT: total thyroidectomy, NTT: near total thyroidectomy.
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withdrawal were performed at 9-12 months after treat-
ment with
131I and when necessary thereafter. The Insti-
tutional Review Board approved the study.
Statistical analysis
The Cox proportional hazards model was used for the
assessment of possible predictors of survival. Variables
with p < 0.20 in the univariate analysis were included
in the multivariate analysis. Forward stepwise metho-
dology was used for the multivariate analysis. Variables
with p < 0.05 were considered statistically significant
in this step. Kaplan-Meier plots were constructed in
order to depict survival. PASW 18.0 (IBM-SPSS Inc.,
Chicago, IL) was used for data analysis. Factors consid-
ered for prediction of survival were summarised in
Table 3.
Results
Fifty-two patients (29 females and 23 males) were found
to have distant metastases. Most patients were above 45
years of age (35 out of 52 patients). Twenty-two patients
(42.3%) had distant metastases at the time of diagnosis
(11 women and 11 men) and 30 patients (57.7%) devel-
oped metastatic disease during follow-up. Tumor size
was ≥ 2 cm in 39 patients. Regional lymph node metas-
tases were present in 30 patients. All patients had total
or near total thyroidectomy. Clinical characteristics of
the patients and specific characteristics of the tumors
are shown in Table 1.
Twenty-four patients had classic papillary thyroid can-
cer, 20 patients follicular variant of papillary cancer, 1
had papillary carcinoma with insular components and 1
patient had columnar cell variant of papillary carcinoma.
The remaining 6 cases exhibited papillary cancer with
low differentiation of the cells (with focal follicular ele-
ments in 2 patients).
The commonest sites of metastatic disease were lung
(32 patients), followed by bone (13 patients), lower med-
iastinum (6 patients) extracervical soft tissue (4
patients), central nervous system (4 patients), pleura (4
patients), liver (1 patient), and oeshophagus (1 patient).
Multiple site metastases were found in 14 patients.
Table 3 indicates the factors affecting survival in our ser-
ies: histology comprised the most significant factor in the
analysis, the classic papillary type carrying significantly
improved survival than follic u l a ra n do t h e rs u b t y p e so f
papillary thyroid cancer. The instant risk of death for the
other histological subtypes was 4.56 times higher than the
risk for the classic papillary type. The other parameters
tested did not affect survival significantly.
Mortality ranged according to age (table 1), with the
worst outcome in patients above 45 years of age. Overall
5-year survival in metastatic papillary thyroid cancer was
88.2%, 10-year 76.6% and 15-year survival 35.8% (for 10
patients). Cumulative survival is shown in Figure 1.
Discussion
Only a few studies so far examined specific factors
affecting survival in patients with PTC, as in most stu-
dies patients with papillary and follicular thyroid cancer
were included. The striking finding in this study was
that histological variant plays the most significant role
in patient’s survival in metastatic PTC. The classic papil-
lary type of PTC demonstrated improved prognosis
compared to other papillary cancer variants.
Table 2 TNM staging of patients at initial diagnosis
Ν0 (n = 20) Ν1 (n = 32) Total (n = 52)
nn n n n
T1 Μ02 Μ01
3 Μ11 3 Μ126
T2 M0 1 M0 2
1 M1 0 3 M1 1 4
T3 M0 10 M0 9
12 M1 2 16 M1 7 28
T4 M0 2 M0 3
4 M1 2 10 M1 7 14
T: tumor, N: lymph nodes, M: metastases, n represents the number of patients
in each category
According to AJCC Cancer Staging Manual, Sixth Edition (2002) published by
Springer-Verlag, Inc., New York.
Table 3 Factors considered for prediction of survival
Factor Significance
Sex 0.523
Age 0.132
Histology 0.004
Multifocality 0.887
Bilaterality 0.292
Type of surgery 0.603
Size of tumor 0.392
Lymph node metastases at operation 0.263
Thyroid parenchyma invasion 0.502
Thyroid capsule invasion 0.095
Extrathyroidal invasion 0.863
Vessel invasion 0.058
Metastatic disease from diagnosis 0.180
First site of metastasis 0.874
Uptake at ablation 0.568
TSH on T4 withdrawal 0.782
Thyroglobulin on T4 withdrawal 0.799
Total 131 I mCi 0.426
Years to metastasis 0.115
Chrisoulidou et al. Thyroid Research 2011, 4:12
http://www.thyroidresearchjournal.com/content/4/1/12
Page 3 of 5Although papillary thyroid carcinoma carries the most
favorable prognosis amongst all types of thyroid cancer,
distant metastatic disease may occur with subsequent
compromise in patient’s survival. Even in the presence
of metastatic disease, papillary thyroid cancer in our ser-
ies has an overall 10-year survival of 76.6%. In general,
disease-related mortality varies greatly in PTC: papillary
microcarcinomas exhibit no mortality at all [18], even in
the presence of distant metastases [19]. In other series
with larger PTCs, 10-year survival ranged from 14-80%
[20-22], with limited survival in older patients. Old age
is a predictor of worse prognosis, although an exact cut
off point was not uniformly identified [23]. In this study,
we did not observe statistical differences in survival
according to age, although we also observed an increase
in mortality in patients above 45 years of age.
Previous studies indicated many factors, as capsular
infiltration, extrathyroidal extension and lymph node
metastases at diagnosis as unfavorable prognostic factors
for persistent disease or recurrences [24]. Cervical
lymph node metastases have been related to poor prog-
nosis occurring synchronously or metachronously to
diagnosis [25], although this was not seen in the present
study. Extranodal invasion and perithyroidal invasion to
muscles and soft tissues showed a higher incidence of
distant metastases and death [26]. The presence of ves-
sel invasion was associated, as in other reports, with
poor prognosis, although in our series this association
had a marginal significance (Table 2).
Although differentiated thyroid cancer is frequently
seen in women, in patients with metastatic PTC the
female: male ratio was 1.26:1, in accordance with the
general notion that male gender adversely affects out-
come in differentiated thyroid cancer. In the studied
group 52% of males and 31% of females died during fol-
low-up, however this was not significant probably due
to small numbers. Histology increased nearly 5-fold the
risk of death in patients with PTC variants other than
the classic papillary type.
In keeping with other reports, we observed lung as the
primary metastatic site, followed by bone, multiple site
involvement and other, less frequently seen, affected
organs. The development of rare metastases, as CNS,
liver and extracervical soft tissue metastases, indicates
the importance of close clinical follow-up in these
patients.
In conclusion, the histological subtype in metastatic
PTC determines survival in a significant way. As a
result, patients with follicular and other uncommon sub-
types of PTC that present with or develop distant meta-
static disease should be vigorously treated with surgery,
where appropriate, radioiodine therapy and should also
be considered for inclusion to studies concerning new
therapies, like tyrosine kinase inhibitors.
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